Breast Cancer [2017]: Bulletin #1
Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: Roche announcing results from the Phase III APHINITY study of Perjeta (pertuzumab) as an adjuvant therapy for BC; Merck & Co. announcing data from the Keytruda (pembrolizumab) I-SPY 2 study; as well as the US approval and launch of Nerlynx (neratinib; Puma Biotechnology).
Business Questions:
Business Questions:
- How do KOLs regard Perjeta’s magnitude of benefit in the APHINITY trial?
- According to KOLs, in which patients will Perjeta be prescribed?
- What are KOLs’ views on Keytruda as a neoadjuvant therapy in triple-negative BC?
- How do KOLs view checkpoint inhibitors in general as potential therapies for BC?
- How do experts foresee Nerlynx being prescribed in the treatment of BC?
- What factors, if any, are likely to impact Nerlynx’s uptake?
